Similar results are shown in a study by Frommert et al. [21] with lower seroconversion response to various types of homologous or heterologous COVID-19 vaccine regimens among AIIRD patients treated with agents such as MTX, MMF, RTX, or Jak-I, but not when treated with anti-TNF-α agents. The gene discussed is TNF; the disease is COVID-19.